

# Table of Contents

<b>1 Summary .....</b>	<b>4</b>
<b>1.1 Summary .....</b>	<b>4</b>
<b>1.2 Zusammenfassung .....</b>	<b>6</b>
<b>2 Introduction .....</b>	<b>9</b>
<b>2.1 Background .....</b>	<b>9</b>
<b>2.2 Tumor angiogenesis.....</b>	<b>9</b>
2.2.1 Tumors depend on angiogenesis .....	10
2.2.2 Anti-angiogenic treatment in cancer therapy .....	24
2.2.3 Challenges of anti-angiogenic therapy .....	29
<b>2.3 Tumor lymphangiogenesis.....</b>	<b>37</b>
2.3.1 Lymphatic vasculature in health.....	38
2.3.2 Lymphangiogenesis: Growth factors and receptors .....	45
2.3.3 Significance of the lymphatic system in disease .....	53
2.3.4 Aims of projects 1 and 2 .....	58
<b>3 Project 1: Molecular profile of tumor-associated blood vascular endothelial cells after short-term sunitinib therapy and identification of a novel biomarker for therapeutic response .....</b>	<b>59</b>
<b>3.1 Introduction .....</b>	<b>59</b>
<b>3.2 Materials and Methods .....</b>	<b>61</b>
<b>3.3 Results .....</b>	<b>65</b>
3.3.1 Short-term sunitinib treatment does not alter the blood vasculature in B16-F10-luc2 tumors, but leads to increased expression of G-CSF .....	65
3.3.2 Microarray analyses reveal an up-regulation of immunological pathways and down- regulation of vascular development after 24 h sunitinib treatment.....	67

3.3.3	Claudin-5 expression is decreased and c-Met expression is increased after sunitinib treatment of tumor bearing mice .....	69
3.3.4	Combinatorial treatment with sunitinib and a c-Met inhibitor reduces tumor size .....	72
3.3.5	Short-term treatment with sunitinib reduces vascular leakage in tumors and in normal back skin .....	72
<b>3.4</b>	<b>Discussion .....</b>	<b>74</b>
<b>4</b>	<b>Project 2: HOXD10 is a major mediator of VEGF-C induced permeability in lymphatic endothelial cells .....</b>	<b>79</b>
<b>4.1</b>	<b>Introduction .....</b>	<b>79</b>
<b>4.2</b>	<b>Materials and Methods .....</b>	<b>81</b>
<b>4.3</b>	<b>Results .....</b>	<b>89</b>
4.3.1	Transcription factors are over-represented among the genes whose expression is up-regulated upon VEGF-C156S treatment of human LECs.....	89
4.3.2	A set of 17 immediate early response transcription factors are rapidly up-regulated upon stimulation of LECs with VEGF-C156S .....	91
4.3.3	HOXD10 is an active mediator of the VEGF-C156S induced transcriptional response in LECs	94
4.3.4	HOXD10 is highly expressed by LECs and is controlled by the lymphatic transcription factor PROX1 .....	98
4.3.5	HOXD10 regulates the expression of ATF3, FOSB and NR4A1 .....	98
4.3.6	HOXD10 is necessary for the induction of NR4A1 downstream of VEGFR-3 signaling	99
4.3.7	HOXD10 over-expressing cells show increased eNOS expression and permeability .	102
4.3.8	HOXD10 affects proliferation, migration and sprouting of LECs .....	103
<b>4.4</b>	<b>Discussion .....</b>	<b>105</b>
<b>5</b>	<b>Conclusion and perspectives .....</b>	<b>110</b>

<b>6</b>	<b>Acknowledgements .....</b>	<b>114</b>
<b>7</b>	<b>Curriculum Vitae.....</b>	<b>116</b>
<b>8</b>	<b>Abbreviations .....</b>	<b>120</b>
<b>9</b>	<b>References .....</b>	<b>125</b>
<b>10</b>	<b>Appendix .....</b>	<b>153</b>